Patents by Inventor Christopher Rohde

Christopher Rohde has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12227768
    Abstract: The present invention relates in part to methods for producing tissue-specific cells from patient samples, and to tissue-specific cells produced using these methods. Methods for reprogramming cells using RNA are disclosed. Therapeutics comprising cells produced using these methods are also disclosed.
    Type: Grant
    Filed: October 3, 2022
    Date of Patent: February 18, 2025
    Assignee: Factor Bioscience Inc.
    Inventors: Matthew Angel, Christopher Rohde
  • Patent number: 12227757
    Abstract: The present invention relates in part to nucleic acids encoding proteins, nucleic acids containing non-canonical nucleotides, therapeutics comprising nucleic acids, methods, kits, and devices for inducing cells to express proteins, methods, kits, and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods for inducing cells to express proteins and for reprogramming and gene-editing cells using RNA are disclosed. Methods for producing cells from patient samples, cells produced using these methods, and therapeutics comprising cells produced using these methods are also disclosed.
    Type: Grant
    Filed: August 5, 2022
    Date of Patent: February 18, 2025
    Assignee: Factor Bioscience Inc.
    Inventors: Matthew Angel, Christopher Rohde
  • Patent number: 12201675
    Abstract: The present invention relates in part to nucleic acids, including nucleic acids encoding proteins, therapeutics and cosmetics comprising nucleic acids, methods for delivering nucleic acids to cells, tissues, organs, and patients, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, therapeutics, and cosmetics produced using these methods, kits, and devices. Methods and products for altering the DNA sequence of a cell are described, as are methods and products for inducing cells to express proteins using synthetic RNA molecules, including cells present in vivo. Therapeutics comprising nucleic acids encoding gene-editing proteins are also described.
    Type: Grant
    Filed: September 6, 2019
    Date of Patent: January 21, 2025
    Assignee: Factor Bioscience Inc.
    Inventors: Matthew Angel, Christopher Rohde
  • Patent number: 12006508
    Abstract: The present invention relates in part to nucleic acids encoding proteins, therapeutics comprising nucleic acids encoding proteins, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods and products for altering the DNA sequence of a cell are described, as are methods and products for inducing cells to express proteins using synthetic RNA molecules. Therapeutics comprising nucleic acids encoding gene-editing proteins are also described.
    Type: Grant
    Filed: June 25, 2020
    Date of Patent: June 11, 2024
    Assignee: Factor Bioscience Inc.
    Inventors: Matthew Angel, Christopher Rohde
  • Publication number: 20240182856
    Abstract: The present disclosure relates in part to engineered immune cells that are, inter alia, silenced from a host immune response.
    Type: Application
    Filed: September 5, 2023
    Publication date: June 6, 2024
    Inventors: Matthew ANGEL, Christopher ROHDE, Mitchell KOPACZ, Jasmine HARRIS, James PAN
  • Publication number: 20240156987
    Abstract: The present invention relates in part to nucleic acids, including nucleic acids encoding proteins, therapeutics and cosmetics comprising nucleic acids, methods for delivering nucleic acids to cells, tissues, organs, and patients, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, therapeutics, and cosmetics produced using these methods, kits, and devices.
    Type: Application
    Filed: June 2, 2023
    Publication date: May 16, 2024
    Inventors: Matthew ANGEL, Christopher ROHDE
  • Patent number: 11904023
    Abstract: The present invention relates in part to nucleic acids, including nucleic acids encoding proteins, therapeutics and cosmetics comprising nucleic acids, methods for delivering nucleic acids to cells, tissues, organs, and patients, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, therapeutics, and cosmetics produced using these methods, kits, and devices.
    Type: Grant
    Filed: September 11, 2020
    Date of Patent: February 20, 2024
    Assignee: Factor Bioscience Inc.
    Inventors: Matthew Angel, Christopher Rohde
  • Publication number: 20240035025
    Abstract: The present disclosure relates, in part, to circular RNAs and engineered variants thereof.
    Type: Application
    Filed: October 3, 2023
    Publication date: February 1, 2024
    Inventors: Matthew ANGEL, Christopher ROHDE, Aisha SVIHLA
  • Publication number: 20230373903
    Abstract: The present invention relates in part to novel cationic lipids and their use, e.g., in delivering nucleic acids to cells.
    Type: Application
    Filed: July 31, 2023
    Publication date: November 23, 2023
    Inventors: Matthew ANGEL, Franklin KOSTAS, Christopher ROHDE
  • Patent number: 11814333
    Abstract: The present invention relates in part to novel cationic lipids and their use, e.g., in delivering nucleic acids to cells.
    Type: Grant
    Filed: December 16, 2021
    Date of Patent: November 14, 2023
    Assignee: Factor Bioscience Inc.
    Inventors: Matthew Angel, Franklin Kostas, Christopher Rohde
  • Publication number: 20230323399
    Abstract: The present invention relates in part to nucleic acids encoding proteins, nucleic acids containing non-canonical nucleotides, therapeutics comprising nucleic acids, methods, kits, and devices for inducing cells to express proteins, methods, kits, and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods for inducing cells to express proteins and for reprogramming and gene-editing cells using RNA are disclosed. Methods for producing cells from patient samples, cells produced using these methods, and therapeutics comprising cells produced using these methods are also disclosed.
    Type: Application
    Filed: June 9, 2023
    Publication date: October 12, 2023
    Inventors: Matthew ANGEL, Christopher ROHDE
  • Publication number: 20230304044
    Abstract: The present invention relates in part to nucleic acids encoding proteins, nucleic acids containing non-canonical nucleotides, therapeutics comprising nucleic acids, methods, kits, and devices for inducing cells to express proteins, methods, kits, and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods for inducing cells to express proteins and for reprogramming and gene-editing cells using RNA are disclosed. Methods for producing cells from patient samples, cells produced using these methods, and therapeutics comprising cells produced using these methods are also disclosed.
    Type: Application
    Filed: June 9, 2023
    Publication date: September 28, 2023
    Inventors: Matthew ANGEL, Christopher ROHDE
  • Publication number: 20230242943
    Abstract: The present invention relates in part to nucleic acids encoding proteins, nucleic acids containing non-canonical nucleotides, therapeutics comprising nucleic acids, methods, kits, and devices for inducing cells to express proteins, methods, kits, and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods for inducing cells to express proteins and for reprogramming and gene-editing cells using RNA are disclosed. Methods for producing cells from patient samples, cells produced using these methods, and therapeutics comprising cells produced using these methods are also disclosed.
    Type: Application
    Filed: August 22, 2022
    Publication date: August 3, 2023
    Inventors: Matthew ANGEL, Christopher ROHDE
  • Patent number: 11708586
    Abstract: The present invention relates in part to nucleic acids encoding proteins, nucleic acids containing non-canonical nucleotides, therapeutics comprising nucleic acids, methods, kits, and devices for inducing cells to express proteins, methods, kits, and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods for inducing cells to express proteins and for reprogramming and gene-editing cells using RNA are disclosed. Methods for producing cells from patient samples, cells produced using these methods, and therapeutics comprising cells produced using these methods are also disclosed.
    Type: Grant
    Filed: June 26, 2020
    Date of Patent: July 25, 2023
    Assignee: Factor Bioscience Inc.
    Inventors: Matthew Angel, Christopher Rohde
  • Patent number: 11692203
    Abstract: The present invention relates in part to nucleic acids encoding proteins, nucleic acids containing non-canonical nucleotides, therapeutics comprising nucleic acids, methods, kits, and devices for inducing cells to express proteins, methods, kits, and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods for inducing cells to express proteins and for reprogramming and gene-editing cells using RNA are disclosed. Methods for producing cells from patient samples, cells produced using these methods, and therapeutics comprising cells produced using these methods are also disclosed.
    Type: Grant
    Filed: June 26, 2020
    Date of Patent: July 4, 2023
    Assignee: Factor Bioscience Inc.
    Inventors: Matthew Angel, Christopher Rohde
  • Publication number: 20230193231
    Abstract: The present invention relates in part to nucleic acids encoding gene editing proteins, including novel engineered variants.
    Type: Application
    Filed: October 11, 2022
    Publication date: June 22, 2023
    Inventors: Matthew ANGEL, Franklin KOSTAS, Mitchell KOPACZ, Christopher ROHDE
  • Publication number: 20230193207
    Abstract: Cell-based therapies based on mesenchymal stem cells (MSCs) are described.
    Type: Application
    Filed: October 14, 2022
    Publication date: June 22, 2023
    Inventors: Matthew Angel, Christopher Rohde, Jasmine Harris
  • Publication number: 20230151335
    Abstract: The present invention relates in part to methods for producing tissue-specific cells from patient samples, and to tissue-specific cells produced using these methods. Methods for reprogramming cells using RNA are disclosed. Therapeutics comprising cells produced using these methods are also disclosed.
    Type: Application
    Filed: October 3, 2022
    Publication date: May 18, 2023
    Inventors: Matthew ANGEL, Christopher ROHDE
  • Publication number: 20230033888
    Abstract: The present invention relates in part to nucleic acids encoding proteins, nucleic acids containing non-canonical nucleotides, therapeutics comprising nucleic acids, methods, kits, and devices for inducing cells to express proteins, methods, kits, and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods for inducing cells to express proteins and for reprogramming and gene-editing cells using RNA are disclosed. Methods for producing cells from patient samples, cells produced using these methods, and therapeutics comprising cells produced using these methods are also disclosed.
    Type: Application
    Filed: August 5, 2022
    Publication date: February 2, 2023
    Inventors: Matthew ANGEL, Christopher ROHDE
  • Publication number: 20230015146
    Abstract: The present invention relates in part to nucleic acids, including nucleic acids encoding proteins, therapeutics and cosmetics comprising nucleic acids, methods for delivering nucleic acids to cells, tissues, organs, and patients, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, therapeutics, and cosmetics produced using these methods, kits, and devices.
    Type: Application
    Filed: August 17, 2022
    Publication date: January 19, 2023
    Inventors: Matthew ANGEL, Christopher ROHDE